日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study

一项开放标签扩展研究评估了nemolizumab治疗特应性皮炎长达2年的安全性和有效性

期刊:Journal of the European Academy of Dermatology and Venereology
影响因子:8
doi:10.1111/jdv.70080
Augustin, Matthias; Tauber, Marie; Sidbury, Robert; Silverberg, Jonathan I; Papp, Kim A; Thaçi, Diamant; De Bruin-Weller, Marjolein S; Reich, Adam; Peris, Ketty; Barber, Kirk; Galus, Ryszard; Kaszuba, Andrzej; Zirwas, Matthew; Nahm, Walter K; Trullenque, Gretel; Maintz, Laura; Alpizar, Sady; Son, Sang Wook; Laquer, Vivian; Gold, Linda Stein; Cheong, Soo Yeon; Ryzhkova, Anna; Drahos, Agnes; Ulianov, Liliana; Piketty, Christophe
发表日期：2026
文献求助 收藏

Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND

特拉洛奇尤单抗治疗中重度特应性皮炎患者长达6年的长期安全性和有效性：开放标签扩展试验ECZTEND的最终结果

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-026-01656-7
Blauvelt, Andrew; Hong, H Chih-Ho; Katoh, Norito; Langley, Richard G; Laquer, Vivian; Lesiak, Aleksandra; Peris, Ketty; Seneschal, Julien; Silvestre, Juan-Francisco; Warren, Richard B; Wollenberg, Andreas; Zirwas, Matthew; Bennike, Niels Højsager; Safavimanesh, Farzaneh; Tindberg, Ann-Marie; Reich, Kristian
发表日期：2026
文献求助 收藏

Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2-11 Years

罗氟司特乳膏0.3%每日一次治疗2-11岁儿童轻度或中度斑块状银屑病的安全性、临床疗效和药代动力学早期证据

期刊:Pediatric Dermatology
影响因子:1.2
doi:10.1111/pde.70013
Hebert, Adelaide A; Guide, Shireen V; Groysman, Vlada; Gonzalez, Mercedes E; Blanco, Daisy; Laquer, Vivian; Seal, Melissa S; Thurston, Archie; Krupa, David; Snyder, Scott; Burnett, Patrick; Chu, David H; Berk, David R; Higham, Robert C
银屑病
发表日期：2026
文献求助 收藏

Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable Study

Lebrikizumab治疗成人和青少年有色皮肤中重度特应性皮炎患者的疗效和安全性：来自IIIb期开放标签ADmirable研究的结果

期刊:American Journal of Clinical Dermatology
影响因子:8.8
doi:10.1007/s40257-025-00970-8
Alexis, Andrew; Moiin, Ali; Waibel, Jill; Wallace, Paul; Cohen, David; Laquer, Vivian; Kwong, Pearl; Atwater, Amber Reck; Schuster, Christopher; Proper, Jennifer; Silk, Maria; Pierce, Evangeline; Pillai, Sreekumar; Rueda, Maria Jose; Moore, Angela
发表日期：2025
文献求助 收藏

The Tralokinumab Pre-Filled Pen Improved Atopic Dermatitis Signs and Symptoms and Was Well Tolerated in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 16-Week, Open-Label, Single-Arm Phase 3 Study (INJECZTRA)

一项为期 16 周的开放标签单臂 3 期研究 (INJECZTRA) 表明，Tralokinumab 预填充注射笔可改善中重度特应性皮炎成人和青少年患者的特应性皮炎体征和症状，且耐受性良好。

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-025-01490-3
Soung, Jennifer; Laquer, Vivian; Zirwas, Matthew; van Iperen, Peter; Stinson, John C; Albertsen, Katrine Lykke; Stein Gold, Linda
发表日期：2025
文献求助 收藏

Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial

Zasocitinib (TAK-279) 抑制酪氨酸激酶 2 治疗银屑病：一项随机临床试验

期刊:Jama Dermatology
影响因子:11
doi:10.1001/jamadermatol.2024.2701
Armstrong, April W; Gooderham, Melinda; Lynde, Charles; Maari, Catherine; Forman, Seth; Green, Lawrence; Laquer, Vivian; Zhang, Xinyan; Franchimont, Nathalie; Gangolli, Esha A; Blau, Jessamyn; Zhao, Yiwei; Zhang, Wenwen; Srivastava, Bhaskar; Heap, Graham; Papp, Kim
信号转导
银屑病
发表日期：2024
文献求助 收藏

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials

Lebrikizumab治疗中重度特应性皮炎成人和青少年患者的安全性：八项临床试验的综合分析

期刊:American Journal of Clinical Dermatology
影响因子:8.8
doi:10.1007/s40257-023-00792-6
Stein Gold, Linda; Thaçi, Diamant; Thyssen, Jacob P; Gooderham, Melinda; Laquer, Vivian; Moore, Angela; Natalie, Chitra R; Zhao, Fangyi; Meskimen, Eric; Elmaraghy, Hany; Montmayeur, Sonia; Gallo, Gaia; Jimenez, Gemma; de Bruin-Weller, Marjolein
发表日期：2023
文献求助 收藏

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

Lebrikizumab治疗中重度特应性皮炎青少年患者的安全性和有效性：一项为期52周的开放标签3期研究

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-023-00942-y
Paller, Amy S; Flohr, Carsten; Eichenfield, Lawrence F; Irvine, Alan D; Weisman, Jamie; Soung, Jennifer; Pinto Correia, Ana; Natalie, Chitra R; Rodriguez Capriles, Claudia; Pierce, Evangeline; Reifeis, Sarah; Gontijo Lima, Renata; Armengol Tubau, Clara; Laquer, Vivian; Weidinger, Stephan
发表日期：2023
文献求助 收藏

Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents

奈莫利珠单抗治疗青少年特应性皮炎的药代动力学、安全性、疗效和生物标志物特征

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-021-00678-7
Sidbury, Robert; Alpizar, Sady; Laquer, Vivian; Dhawan, Sunil; Abramovits, William; Loprete, Luca; Krishnaswamy, Jayendar Kumar; Ahmad, Faiz; Jabbar-Lopez, Zarif; Piketty, Christophe
发表日期：2022
文献求助 收藏

"Peeling paint" dermatosis in a leukemia patient

白血病患者出现“油漆剥落样”皮炎

期刊:JAAD Case Reports
影响因子:
doi:10.1016/j.jdcr.2020.02.005
Juhasz, Margit; Laquer, Vivian; Jerkins, James; Smith, Janellen
白血病
发表日期：2020
文献求助 收藏